FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- RANGE RESOURCES CORPORATION (NYSE: RRC) today announced its fourth quarter 2025 financial results and plans for 2026. Full-Year 2025 Highlights – Cash flow from operating activities of $1.2 billionCash flow from operations, before working capital changes, of $1.3 billionSigned 10-year supply agreement for 75 Mmcf per day for a Midwest power plantProduction averaged 2.24 Bcfe per day, comprised of approximately 69% natural gasAll-in capital spending of $6 ...

DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-04 ...

JACKSONVILLE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Regency Centers Corporation (“Regency” or the “Company”) (Nasdaq: REG) today announced that the Company’s management team is scheduled to present at the 2026 Citi Global Property CEO Conference (the “Conference”) on Monday, March 2, 2026, at 8:50 am ET. To access the Company’s live presentation, use the webcast registration link below. Regency Centers PresentationDate:Monday, March 2, 2026Time:8:50 a.m. – 9:25 a.m. ETWebcast Link:Citi's 2026 Global Prope ...

BENBROOK, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Tandy Leather Factory, Inc. (Nasdaq: TLF) today announced the Company’s financial results for the fourth fiscal quarter and full year 2025. Highlights from 2025: Revenues were $76.3 million, up 2.6% from 2024Generated operating loss of $1.0 million versus income of $0.6 million in 2024Net income of $9.1 million versus $0.8 million in 2024Gross margins of 57.0%, up from 56.2% in 2024Operating expenses $44.5 million, up 8.1% from 2024Adjusted EBITDA* (from op ...

BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025. Recent Highlights: Fourth quarter 2025 revenue from Continuing Operations of $23.8 million; Full Year 2025 revenue of $85.3 millionFully operationalized over $40 million in previously announced annualized cost savings supporting path to positive adjusted EBITDA and adjusted cash flow exiting 202 ...

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Comp ...

Stock Repurchase Program - Valley National Bancorp's Board of Directors approved a new stock repurchase program for up to 25 million shares of common stock, effective from April 27, 2026, to April 27, 2028 [1][2] - The current stock repurchase program is set to expire on April 26, 2026, unless terminated sooner [1] Repurchase Methods and Flexibility - Repurchases can be conducted through various methods, including open market purchases and Rule 10b5-1 trading plans, in compliance with SEC regulations [2] - The program does not obligate Valley to acquire a specific number of shares and can be suspended or discontinued at the company's discretion [2] Company Overview - Valley National Bank, a regional financial institution and principal subsidiary of Valley National Bancorp, has approximately $64 billion in assets and operates over 200 offices across several states [3] - The bank offers a full range of consumer, commercial, and wealth management solutions, emphasizing a relationship-led approach to support community investment and corporate citizenship [3]

Fourth Quarter Highlights† Reported revenue of $393.9 million, up 11%Constant currency revenue* and constant currency revenue, organic* up 10% and up 7%, respectivelyGAAP operating margin of 13.8%, compared to 10.3% in prior year periodNon-GAAP operating margin* of 21.0%, compared to 19.6% in prior year periodGAAP EPS $0.63, up 37%Non-GAAP EPS* $1.04, up 12%Free cash flow* generation of $74.0 million, up 13% Fiscal Year 2025 Highlights† Reported revenue of $1.516 billion, up 12%Constant currency revenue* an ...

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Exp ...

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 at 9:50 a.m. ET. To listen to a live webcast of this event, or access an archived we ...